Roth Capital Comments on New SERM Lasofoxifene Phase 1 Data
Tweet Send to a Friend
Roth Capital affirms Ligand Pharmaceuticals, Inc. (Nasdaq: LGND) at Buy with a price target of $92 following a positive update ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE